Acemannan accelerates cell proliferation and skin wound healing through AKT/mTOR signaling pathway
Acemannan accelerates cell proliferation and skin wound healing through AKT/mTOR signaling pathway
复制标题
Acemannan 通过 AKT/mTOR 信号通路加速细胞增殖和皮肤伤口愈合
DOI:
10.1016/j.jdermsci.2015.03.016
复制
发表时间:
2015-08-01
影响因子:
4.6
通讯作者:
Xu, Xiang
中科院分区:
文献类型:
--
作者:
Xing, Wei;Guo, Wei;Xu, Xiang
Background: Acemannan is a bioactive polysaccharides promoting tissue repair. However, the roles of acemannan in skin wound healing and the underlying molecular mechanisms are largely unclear.Objective: The goal of this study is to investigate the positive role of acemannan in cutaneous wound healing and its mechanism.Methods: Mouse skin wound model and skin primary fibroblasts were used to demonstrate the positive effect of acemannan on cutaneous wound healing. The expressions of cell proliferation nuclear antigen ki-67, cyclin D1 and activity of AKT/mTOR signaling were analyzed in acemannan-treated fibroblasts and mice. Rapamycin and AKT inhibitor VIII were used to determine the key role of AKT/mTOR signaling in acemannan-promoting cutaneous wound healing.Results: We found that acemannan significantly accelerated skin wound closure and cell proliferation. Acemannan promoted the expression of cyclin D1 in cultured fibroblasts, which was mediated by AKT/mTOR signal pathway leading to enhanced activity of the eukaryotic translation initiation factor-4F (eIF4F) and increased translation of cyclin D1. In contrast, pharmaceutical blockade of AKT/mTOR signaling by mTOR inhibitor rapamycin or AKT inhibitor VIII abolished acemannan-induced cyclin D1 translation and cell proliferation. In vivo studies confirmed that the activation of AKT/mTOR by acemannan played a key role in wound healing, which could be reversed by rapamycin.Conclusion: Acemannan promoted skin wound healing partly through activating AKT/mTOR-mediated protein translation mechanism, which may represent an alternative therapy approach for cutaneous wound. (C) 2015 Published by Elsevier Ireland Ltd on behalf of Japanese Society for Investigative Dermatology.